S Mustjoki Selected Research

S Mustjoki Research Topics

9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2017 - 11/2007
7	Leukemia 01/2021 - 12/2000
3	Neoplasms (Cancer) 01/2018 - 12/2000
3	Lymphocytosis 10/2011 - 11/2007
2	Philadelphia Chromosome 07/2013 - 01/2010
1	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2018
1	Blast Crisis (Blast Phase) 05/2015
1	Large Granular Lymphocytic Leukemia 04/2015
1	Thrombocytopenia (Thrombopenia) 04/2013
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2013
1	Pleural Effusion (Pleural Effusions) 04/2013
1	Disease Progression 06/2001
1	Circulating Neoplastic Cells 12/2000
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2000
1	Pathologic Processes 12/2000

5	Dasatinib (BMS 354825)FDA Link 01/2016 - 08/2009
4	Tyrosine Kinase InhibitorsIBA 01/2017 - 01/2010
3	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 11/2007
3	Pharmaceutical PreparationsIBA 05/2015 - 04/2013
2	tinostamustineIBA 01/2021 - 01/2020
2	Thomsen-Friedenreich antibodiesIBA 01/2021 - 01/2020
1	nilotinib FDA Link 10/2017
1	Immunomodulating AgentsIBA 01/2017
1	InterferonsIBA 01/2016
1	amsonic acid (DAS)IBA 01/2016
1	Methotrexate (Mexate)FDA LinkGeneric 04/2015
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 06/2001
1	PlasminogenIBA 12/2000
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 12/2000
1	Urokinase Plasminogen Activator ReceptorsIBA 12/2000

9	Therapeutics 01/2018 - 11/2007
1	Drug Therapy (Chemotherapy) 12/2000